Mineralys Therapeutics, Inc. $MLYS Shares Acquired by Hennion & Walsh Asset Management Inc.

Hennion & Walsh Asset Management Inc. boosted its holdings in Mineralys Therapeutics, Inc. (NASDAQ:MLYS) by 70.0% during the 3rd quarter, Holdings Channel reports. The fund owned 52,848 shares of the company’s stock after acquiring an additional 21,753 shares during the quarter. Hennion & Walsh Asset Management Inc.’s holdings in Mineralys Therapeutics were worth $2,004,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently added to or reduced their stakes in the business. Mirae Asset Global Investments Co. Ltd. boosted its position in Mineralys Therapeutics by 51.0% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,518 shares of the company’s stock worth $34,000 after acquiring an additional 850 shares during the period. Ameritas Investment Partners Inc. raised its stake in shares of Mineralys Therapeutics by 42.8% during the second quarter. Ameritas Investment Partners Inc. now owns 3,995 shares of the company’s stock valued at $54,000 after purchasing an additional 1,197 shares in the last quarter. KLP Kapitalforvaltning AS bought a new stake in shares of Mineralys Therapeutics during the second quarter valued at about $91,000. Police & Firemen s Retirement System of New Jersey lifted its holdings in Mineralys Therapeutics by 29.4% in the second quarter. Police & Firemen s Retirement System of New Jersey now owns 9,234 shares of the company’s stock worth $125,000 after purchasing an additional 2,098 shares during the period. Finally, ProShare Advisors LLC bought a new position in Mineralys Therapeutics in the 2nd quarter valued at about $141,000. Institutional investors own 84.46% of the company’s stock.

Mineralys Therapeutics Price Performance

MLYS stock opened at $33.13 on Friday. The firm has a market cap of $2.62 billion, a PE ratio of -11.23 and a beta of 0.49. Mineralys Therapeutics, Inc. has a 12 month low of $8.24 and a 12 month high of $47.65. The firm has a 50 day simple moving average of $39.15 and a 200 day simple moving average of $30.26.

Mineralys Therapeutics (NASDAQ:MLYS) last posted its quarterly earnings results on Monday, November 10th. The company reported ($0.52) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.66) by $0.14. As a group, sell-side analysts expect that Mineralys Therapeutics, Inc. will post -4.23 earnings per share for the current year.

Wall Street Analyst Weigh In

MLYS has been the topic of a number of recent analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Mineralys Therapeutics in a research report on Wednesday, October 8th. Wells Fargo & Company boosted their target price on Mineralys Therapeutics from $50.00 to $55.00 and gave the stock an “overweight” rating in a report on Tuesday, November 11th. Stifel Nicolaus upped their target price on Mineralys Therapeutics from $45.00 to $52.00 and gave the stock a “buy” rating in a research report on Friday, December 19th. Finally, HC Wainwright increased their price target on Mineralys Therapeutics from $52.00 to $56.00 and gave the company a “buy” rating in a research note on Wednesday, November 12th. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $47.43.

Insider Activity at Mineralys Therapeutics

In other Mineralys Therapeutics news, Director Daphne Karydas sold 15,000 shares of the business’s stock in a transaction dated Thursday, November 13th. The stock was sold at an average price of $45.99, for a total transaction of $689,850.00. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Alexander M. Gold sold 12,742 shares of the company’s stock in a transaction dated Thursday, November 13th. The shares were sold at an average price of $46.50, for a total transaction of $592,503.00. The disclosure for this sale is available in the SEC filing. Insiders sold 1,668,178 shares of company stock valued at $70,871,538 over the last ninety days. Company insiders own 25.56% of the company’s stock.

Mineralys Therapeutics Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.